Company Overview

Cocrystal Pharma, Inc. is a clinical-stage biotechnology company focused on discovering and developing antiviral therapeutics for infectious diseases. The company operates within the biopharmaceutical and drug development industries, with a primary emphasis on small-molecule antiviral drug candidates targeting viral replication mechanisms. Its research programs have historically focused on influenza, COVID-19, norovirus, and hepatitis C virus (HCV), with revenue generation primarily tied to licensing arrangements, collaboration agreements, and financing activities rather than commercialized product sales.

The company’s strategy is centered on structure-based drug discovery technology designed to develop broad-spectrum antiviral compounds that target highly conserved regions of viral proteins. Cocrystal Pharma was formed in 2014 through a merger involving Biozone Pharmaceuticals and Cocrystal Discovery, Inc., after which the company adopted the Cocrystal Pharma name and shifted its strategic focus toward antiviral therapeutics. The company has positioned itself as a specialized antiviral developer leveraging computational chemistry, structural biology, and medicinal chemistry capabilities to pursue therapies intended to reduce the risk of viral resistance.

Business Operations

Cocrystal Pharma operates primarily as a single biotechnology research and development business focused on antiviral therapeutics. Its operations are concentrated on preclinical and clinical drug development programs, including oral antiviral candidates targeting influenza and coronaviruses. Key assets have included influenza polymerase inhibitor candidates and coronavirus protease inhibitor programs. The company generates limited operating revenue through collaboration and licensing agreements while funding development activities through equity offerings, strategic partnerships, and other capital market activities disclosed in SEC filings.

The company’s operations are headquartered in the United States, with research collaborations and scientific relationships extending internationally. Cocrystal has historically worked with academic institutions, contract research organizations, and pharmaceutical collaborators to support drug discovery and clinical development. The company has also utilized proprietary structure-guided technologies and computational platforms to identify antiviral compounds. Public disclosures identify partnerships and research collaborations associated with pandemic-related antiviral development, including work connected to broad-spectrum coronavirus therapeutics.

Strategic Position & Investments

Cocrystal Pharma’s strategic direction is focused on advancing clinical-stage antiviral candidates while expanding its proprietary drug discovery platform into additional infectious disease indications. The company has emphasized oral antiviral therapies that target viral enzymes with high conservation across strains, aiming to address resistance challenges and future viral mutations. Its development priorities have included influenza antivirals and pan-coronavirus therapeutic candidates, particularly following heightened industry focus on pandemic preparedness and respiratory infectious diseases.

The company has pursued collaborations and research alliances rather than large-scale acquisitions, reflecting its relatively small size and clinical-stage business model. Cocrystal has invested in advancing proprietary antiviral libraries, structure-based discovery tools, and preclinical testing capabilities. Publicly available information indicates continued investment in clinical trials and regulatory advancement for lead antiviral candidates. Data regarding material subsidiary expansion or large portfolio-company ownership is inconclusive based on available public sources.

Geographic Footprint

Cocrystal Pharma is headquartered in Bothell, Washington, United States, and primarily operates within the United States biotechnology sector. Its research, clinical development, and regulatory activities are centered in North America, although the company engages with international scientific collaborators, manufacturers, and research service providers as part of its development programs.

The company’s market and operational exposure extend to broader global pharmaceutical and infectious disease markets due to the international relevance of antiviral therapies. Clinical development activities and intellectual property protections are intended to support potential commercialization opportunities across multiple regions, including North America, Europe, and parts of Asia-Pacific. However, the company does not currently maintain the extensive commercial infrastructure associated with large multinational pharmaceutical companies.

Leadership & Governance

Cocrystal Pharma’s leadership team is composed of biotechnology executives and scientific personnel with experience in antiviral drug development, pharmaceutical operations, and public company management. The company’s governance approach has emphasized advancing clinical-stage assets, maintaining intellectual property protection, and leveraging scientific partnerships to support long-term antiviral development programs.

Key executives and leadership figures include:

• Sam Lee, Ph.D. – President and Chief Executive Officer
• James Martin – Chief Financial Officer
• Phillip A. Frost, M.D. – Chairman of the Board
• Wayne Gendreau, M.D. – Chief Medical Officer

The company’s leadership philosophy, as reflected in public filings and investor communications, centers on targeted antiviral innovation, disciplined capital allocation, and the development of therapeutics designed to address unmet needs in infectious diseases through structure-based drug discovery technologies.